Mascalzoni Deborah, Dove Edward S, Rubinstein Yaffa, Dawkins Hugh J S, Kole Anna, McCormack Pauline, Woods Simon, Riess Olaf, Schaefer Franz, Lochmüller Hanns, Knoppers Bartha M, Hansson Mats
1] Center for Research Ethics and Bioethics Uppsala University, Uppsala, Sweden [2] Center for Biomedicine, EURAC Research, Bolzano, Italy.
Centre of Genomics and Policy, Mc Gill University, Montreal, Quebec, Canada.
Eur J Hum Genet. 2015 Jun;23(6):721-8. doi: 10.1038/ejhg.2014.197. Epub 2014 Sep 24.
There is a growing international agreement on the need to provide greater access to research data and bio-specimen collections to optimize their long-term value and exploit their potential for health discovery and validation. This is especially evident for rare disease research. Currently, the rising value of data and bio-specimen collections does not correspond with an equal increase in data/sample-sharing and data/sample access. Contradictory legal and ethical frameworks across national borders are obstacles to effective sharing: more specifically, the absence of an integrated model proves to be a major logistical obstruction. The Charter intends to amend the obstacle by providing both the ethical foundations on which data sharing should be based, as well as a general Material and Data Transfer Agreement (MTA/DTA). This Charter is the result of a careful negotiation of different stakeholders' interest and is built on earlier consensus documents and position statements, which provided the general international legal framework. Further to this, the Charter provides tools that may help accelerate sharing. The Charter has been formulated to serve as an enabling tool for effective and transparent data and bio-specimen sharing and the general MTA/DTA constitutes a mechanism to ensure uniformity of access across projects and countries, and may be regarded as a consistent basic agreement for addressing data and material sharing globally. The Charter is forward looking in terms of emerging issues from the perspective of a multi-stakeholder group, and where possible, provides strategies that may address these issues.
对于提供更多获取研究数据和生物样本库的机会以优化其长期价值并挖掘其在健康发现与验证方面的潜力,国际上达成的共识日益增多。这在罕见病研究中尤为明显。目前,数据和生物样本库价值的不断提升并未伴随数据/样本共享及数据/样本获取方面同等程度的增长。跨国界相互矛盾的法律和伦理框架是有效共享的障碍:更具体地说,缺乏一个综合模式被证明是一个主要的后勤障碍。本宪章旨在通过提供数据共享应基于的伦理基础以及一份通用的材料和数据转移协议(MTA/DTA)来消除这一障碍。本宪章是不同利益相关者利益经过仔细协商的结果,它建立在早期的共识文件和立场声明之上,这些文件提供了总体的国际法律框架。此外,宪章提供了可能有助于加速共享的工具。制定本宪章是为了成为有效且透明的数据和生物样本共享的促进工具,通用的MTA/DTA构成了一种机制,以确保项目和国家之间获取的一致性,并且可以被视为全球处理数据和材料共享的一致基本协议。本宪章从多利益相关者群体的角度对新出现的问题具有前瞻性,并在可能的情况下提供了可解决这些问题的策略。